PMID- 35726778
OWN - NLM
STAT- MEDLINE
DCOM- 20220715
LR  - 20220807
IS  - 2050-7518 (Electronic)
IS  - 2050-750X (Linking)
VI  - 10
IP  - 27
DP  - 2022 Jul 13
TI  - Poly-l-lysine derivative-coated black phosphorus as a nanoplatform for 
      photothermal chemotherapy to enhance anti-tumor efficiency.
PG  - 5191-5202
LID - 10.1039/d1tb02456f [doi]
AB  - Severe systemic toxicity and side effects are major obstacles to the success of 
      chemotherapy for tumors. Regardless of the choice of chemotherapy drugs, the 
      safety of drug delivery materials is crucial, and therefore, there have been 
      various efforts to improve the therapeutic effect and the biological safety of 
      drug delivery systems (DDSs). In this study, a dual stimulus-response DDS 
      (PLL-SS@DOX-BP) was constructed based on the biomaterials of black phosphorus 
      (BP) nanosheets and poly-l-lysine (PLL) to enhance the treatment of doxorubicin 
      hydrochloride (DOX) for breast cancer. The PLL derivative was nano-coated on the 
      surface of drug-loaded BP nanosheets, and it prevented premature leakage of the 
      drug and maintained the stability of the DDS. The introduced disulfide bonds and 
      photothermal agent BP enabled the redox and near-infrared responsive drug release 
      of the DDS, and the coated PLL derivative on the nanocarrier decreased premature 
      leakage of the drug before the DDS reached the tumor tissues. The in vitro and in 
      vivo experiments showed that the combination of biomaterial (PLL) and 
      photothermal material (BP nanosheets) exhibited excellent biological safety and 
      remarkable drug delivery capacity. Moreover, the pharmacodynamic studies 
      indicated that PLL-SS@DOX-BP is a powerful vehicle for photothermal therapy in 
      combination with chemotherapy. Compared with chemotherapy alone, the developed 
      DDS displayed enhanced anti-tumor efficiency with decreased systemic toxicity, 
      and thus, it has the potential to be a promising anti-tumor treatment strategy.
FAU - Li, Anning
AU  - Li A
AD  - Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 
      Liaoning, 110016, P. R. China. zhangpengspu@163.com.
FAU - Wang, Siqi
AU  - Wang S
AD  - Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 
      Liaoning, 110016, P. R. China. zhangpengspu@163.com.
FAU - Zhang, Zhiqiang
AU  - Zhang Z
AD  - School of Pharmacy, Xiamen Medical College, Xiamen, 361023, P. R. China. 
      zifeiyuxq@163.com.
FAU - Xu, Na
AU  - Xu N
AD  - Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 
      Liaoning, 110016, P. R. China. zhangpengspu@163.com.
FAU - Ling, Guixia
AU  - Ling G
AD  - Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 
      Liaoning, 110016, P. R. China. zhangpengspu@163.com.
FAU - Zhang, Peng
AU  - Zhang P
AUID- ORCID: 0000-0002-6881-9800
AD  - Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 
      Liaoning, 110016, P. R. China. zhangpengspu@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220713
PL  - England
TA  - J Mater Chem B
JT  - Journal of materials chemistry. B
JID - 101598493
RN  - 0 (Biocompatible Materials)
RN  - 25104-18-1 (Polylysine)
RN  - 27YLU75U4W (Phosphorus)
SB  - IM
MH  - Biocompatible Materials/chemistry
MH  - *Breast Neoplasms/pathology
MH  - Female
MH  - Humans
MH  - *Nanoparticles/chemistry
MH  - Phosphorus/chemistry
MH  - Phototherapy
MH  - Polylysine
EDAT- 2022/06/22 06:00
MHDA- 2022/07/16 06:00
CRDT- 2022/06/21 06:53
PHST- 2022/06/22 06:00 [pubmed]
PHST- 2022/07/16 06:00 [medline]
PHST- 2022/06/21 06:53 [entrez]
AID - 10.1039/d1tb02456f [doi]
PST - epublish
SO  - J Mater Chem B. 2022 Jul 13;10(27):5191-5202. doi: 10.1039/d1tb02456f.